Fewer than one in 10 individuals who could benefit from GLP-1 drugs such as Wegovy are able to get them, states the WHO as it publishes its initial guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for more widespread and fairer availability to these injectable treatments.
Based on estimates, more than two billion will be living with obesity by 2030 unless action is taken.
"The latest guidelines acknowledges that obesity is a long-term condition that can be treated with holistic and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are key barriers to widespread access to the treatments that can assist patients in reducing considerable weight, explains the agency.
Skinny Jab Shortage
Even in the present best projected case, the supply of such drugs could only cover about 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The advice urges nations and manufacturers to increase access, by approaches like licensing agreements.
A patent on the active ingredient – the primary component of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase satiety so people consume fewer calories.
People commonly see weight reduction within a few weeks of commencing the weekly injections.
Research points to users may see weight return within a year of halting the drug, because their normal appetite come back.
To be carrying excess weight elevates your chance for contracting medical conditions, like type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity impacts individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, according to the health agency.
